logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
6/7/2021 7:34:08 AM Alnylam Announces Positive Results From Phase 3b Study Conducted To Evaluate Safety, Efficacy And PK Of Patisiran
6/1/2021 7:06:10 AM Alnylam Pharma Completes Enrollment In APOLLO-B Phase 3 Study Of Patisiran In ATTR Patients With Cardiomyopathy
5/11/2021 7:04:48 AM Alnylam Pharma Begins Clinical Study Of Biannual Dosing Regimen Of Vutrisiran For Transthyretin-mediated Amyloidosis
5/3/2021 7:06:38 AM Alnylam Pharma Announces Positive Early Results From ILLUMINATE-A Phase 3 Study Of OXLUMO
4/29/2021 8:04:53 AM Alnylam Pharma Q1 GAAP Loss Per Share $1.71; Non-GAAP Loss Per Share $1.64
3/23/2021 8:03:01 AM Alnylam To Present Full 9-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran At AAN Virtual Annual Meeting 2021
2/11/2021 8:05:31 AM Alnylam Q4 GAAP Loss/Shr $2.09 Vs Loss $2.47 Prior Year
1/7/2021 7:05:29 AM Alnylam Reports Positive Topline Results From HELIOS-A Phase 3 Study Of Vutrisiran
12/21/2020 8:03:21 AM Alnylam Appoints Tolga Tanguler As Chief Commercial Officer
12/15/2020 7:03:56 AM Alnylam Says Remains On Track To Report Topline Results From The HELIOS-A Study Of Vutrisiran In Early 2021
12/3/2020 8:09:52 AM Alnylam Reports Full Patient Enrollment In Its ILLUMINATE-C Phase 3 Study Of Lumasiran
12/3/2020 8:08:50 AM Orsini Specialty Pharmacy Expands Partnership With Alnylam As A Limited Distribution Partner For OXLUMO